(Q40314536)

19 September 2017

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer (English)

1 reference

19 September 2017

2

1 reference

19 September 2017

5

1 reference

19 September 2017

A W Tolcher

1

1 reference

19 September 2017

A Ferrari

3

1 reference

19 September 2017

F Ahmann

4

1 reference

19 September 2017

T Drake

6

1 reference

19 September 2017

A Keating

7

1 reference

19 September 2017

J S de Bono

8

1 reference

19 September 2017

22 August 2011

1 reference

19 September 2017

1 reference

19 September 2017

23

1 reference

19 September 2017

4

1 reference

19 September 2017

968-973

1 reference

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

19 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Survivin mediates resistance to antiandrogen therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Survivin expression is associated with features of biologically aggressive prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Development of the VCaP androgen-independent model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR353

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR353

1 reference

19 September 2017

1 reference